JYNT
The Joint Corp.
JYNT's fundamentals are strong and it looks cheap: trading at 33x earnings, about half its usual 70x. Analysts expect strong earnings growth, though they disagree widely on how much.
JYNT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Healthy |
JYNT's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
JYNT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 21x | $6.69 | — |
| Current | 33x | $6.69 | — |
| Cheap | 44x | $8.80 | +32% |
| Fair | 70x | $13.93 | +108% |
| Expensive | 110x | $22.06 | +230% |
Historical ranges are pointers, not guarantees.
JYNT's PE is in its cheap range at 33x. If earnings grow as analysts expect, today's price would be 21x next year's earnings.
JYNT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect JYNT's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
JYNT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.33 | +63% |
| Q3 2026 | $0.20 | +54% |
| Q2 2026 | $0.27 | +$0.41 |
| Q1 2026 | $0.23 | +$0.62 |
| Q4 2025 | $0.20 | +$0.59 |
| Q3 2025 | $0.13 | +$1.26 |
| Q2 2025 | -$0.14 | +$0.83 |
| Q1 2025 | -$0.39 | +$0.36 |
| Q4 2024 | -$0.39 | +$0.26 |
JYNT's earnings per share have fallen from their peak: $0.20 over the past year, against $1.19 in late 2021.
JYNT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $13.6M | +1.3% |
| Q2 2026 | $15.2M | +14% |
| Q1 2026 | $14.8M | +13% |
| Q4 2025 | $15.2M | +3.1% |
| Q3 2025 | $13.4M | -56% |
| Q2 2025 | $13.3M | -56% |
| Q1 2025 | $13.1M | -56% |
| Q4 2024 | $14.7M | -52% |
JYNT's revenue has grown year over year for four quarters in a row: $14M last quarter, up 1.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.8% | +8.6 points |
| Q2 2026 | -2.4% | +6.2 points |
| Q1 2026 | 5.9% | +11 points |
| Q4 2025 | 4.9% | -0.6 points |
| Q3 2025 | 1.2% | +12 points |
| Q2 2025 | -8.6% | +3 points |
| Q1 2025 | -5.2% | -8.9 points |
| Q4 2024 | 5.5% | +6 points |
JYNT's operating margin was 9.8% last quarter, up 8.6 points from the same quarter a year ago.
JYNT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$508.6K | -135% |
| Q2 2026 | $1.9M | +432% |
| Q1 2026 | -$1.7M | +$2.3M |
| Q4 2025 | $2.5M | -34% |
| Q3 2025 | $1.5M | -55% |
| Q2 2025 | $363.6K | +$1.6M |
| Q1 2025 | -$4M | -267% |
| Q4 2024 | $3.8M | +73% |
JYNT usually generates cash, though not every quarter: the latest was −$508,635, but it generated $2M over the past year.
JYNT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.5% | -215K shares |
| 1 year | -8.9% | -1.4M shares |
| 3 years | -6.6% | -984K shares |
| 5 years | -6.3% | -938K shares |
| Available history | -3% | -436K shares |
JYNT has 14M diluted shares, down 8.9% from a year ago, with $15M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.8M |
| Q2 2026 | $676,810 |
| Q1 2026 | $1.1M |
| Q4 2025 | $9M |
| Q3 2025 | $2.3M |
| Q2 2025 | — |
| Q1 2025 | $8,440 |
| Q4 2024 | — |
JYNT spent $15M buying back its own shares over the past year, about six times what it spent the year before.
JYNT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.5x | Net Cash |
| Q2 2026 | -7.1x | Net Cash |
| Q1 2026 | -8.9x | Net Cash |
| Q4 2025 | -31.2x | Net Cash |
| Q3 2025 | -39.9x | Net Cash |
| Q3 2024 | -180.9x | Net Cash |
| Q2 2024 | -5.0x | Net Cash |
| Q1 2024 | -2.5x | Net Cash |
JYNT has more cash than debt.
JYNT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.4 | Neutral |
| Stochastic | 9.3 | Oversold |
JYNT's weekly RSI is 32 (neutral) and its Stochastic is 9 (oversold).
JYNT PE vs Healthcare Sector
| Metric | JYNT | Sector median | Relative |
|---|---|---|---|
| PE | 33x | 26x | 29% above |
| PE % | 5 | 29 | 24 pts below |
JYNT is trading at 33x earnings, a 29% premium to the Healthcare sector's median of 26x.
JYNT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.17 | 6.7% below |
| 20 week MA | $7.96 | 16% below |
| 50 week MA | $8.54 | 22% below |
| 100 week MA | $9.49 | 30% below |
| 200 week MA | $10.9 | 39% below |
JYNT is in a downtrend: it's below all five of its weekly moving averages, and 39% below its 200-week average.
JYNT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.3 | $25.5 | +57% |
| 2021 | $25.5 | $64.7 | +153% |
| 2022 | $64.7 | $15.1 | -77% |
| 2023 | $15.1 | $9.61 | -36% |
| 2024 | $9.61 | $9.90 | +3% |
| 2025 | $9.90 | $8.76 | -12% |
| 2026 YTD | $8.76 | $6.69 | -24% |
JYNT's yearly returns have swung widely, from +153% in 2021 to −77% in 2022. It's down 24% so far in 2026.